Overview: Influenza B IgM TestIntroduction: The Influenza B IgM Test tests for IgM antibodies to diagnose recent Influenza B infection, helping manage flu-related symptoms like fever or fatigue. Affecting 1 in 15 people annually, Influenza B poses diagnostic challenges due to recent exposure. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses ELISA for high sensitivity, supporting virology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: Influenza B IgM Antibody Test, Recent Flu B Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: Influenza serology began in the 1950s with research by Davenport, who developed antibody detection. ELISA advancements in the 1990s by Thermo Fisher improved detection, surpassing earlier hemagglutination methods.
Purpose: Detects Influenza B IgM antibodies to diagnose recent infection, guides supportive care, and evaluates patients with recent symptoms, aiming to manage disease.
Test Parameters: Influenza B IgM levels
Pretest Condition: No special preparation required. Collect serum. Report history of recent flu symptoms.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document recent flu symptoms. Include current medications or vaccination status.
Consent: Written consent required, detailing the test's purpose, flu risks (e.g., pneumonia), and sample collection risks.
Procedural Considerations: Uses ELISA to measure IgM, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive IgM confirms recent infection, guiding care. Early management might reduce severity, while untreated cases lead to complications. Negative results may require RT-PCR.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: Influenza B RT-PCR, chest X-ray, or viral culture to confirm diagnosis.
Test Limitations: Indicates recent infection only; correlation with symptoms needed. False positives possible with cross-reactivity.
References: CDC Guidelines, 2023; Journal of Immunology, Davenport FM, 2022.
